Survivinand Granzyme B–induced apoptosis, a novel anticancer therapy
Authors:
- 1 March 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (3) , 693-703
Abstract
Survivin is an antiapoptotic protein highly expressed in malignant cells that confers resistance to cytotoxic therapy. Granzyme B is a potent cytotoxic protein that is released from mammalian natural killer cells and CTLs following noxious stimuli, including foreign invaders. Here, we took advantage of the properties of these two functionally divergent molecules to create a molecular agent that specifically activates Granzyme B within tumor cells. We designed Survivin and Granzyme B–induced apoptosis (SAGA), which consists of a fusion of the Survivin gene promoter to the coding sequence of active Granzyme B. In cultured human tumor cells transfected with SAGA DNA, Granzyme B is rapidly expressed and results in significant tumor cell death. In vivo, mice harboring human ovarian tumors had statistically significant clinical responses to SAGA treatment that were magnified following combination therapy with SAGA and paclitaxel. At the completion of a 3-week therapeutic trial, 3 of 15 animals were free of disease in the SAGA-treated group, and an additional eight animals had tumors that were nonpalpable and only detected on surgical resection. In contrast, 15 of 15 animals in the control and paclitaxel-only–treated groups had tumors at end of therapy. Treatment with SAGA with or without paclitaxel also prevented disease dissemination in 19 of 20 animals. These results strongly suggest that SAGA has the potential to be a potent agent for the treatment of primary and recurrent human ovarian carcinoma. Moreover, we predict that SAGA will be useful therapeutically in any human cancer that expresses Survivin. [Mol Cancer Ther 2006;5(3):693–703]Keywords
This publication has 39 references indexed in Scilit:
- Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent mannerJournal of Experimental Medicine, 2005
- Molecular Ordering of the Caspase Activation Cascade Initiated by the Cytotoxic T Lymphocyte/Natural Killer (CTL/NK) Protease Granzyme BJournal of Biological Chemistry, 2005
- Survivin splice variants regulate the balance between proliferation and cell deathOncogene, 2005
- Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrenceInternational Journal of Cancer, 2004
- Use of suicide genes for cancer gene therapy: study of the different approachesExpert Opinion on Biological Therapy, 2004
- Transcriptional targeting of tumors with a novel tumor-specific survivin promoterCancer Gene Therapy, 2004
- Validating survivin as a cancer therapeutic targetNature Reviews Cancer, 2003
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Granule-mediated Killing: Pathways for Granzyme B–initiated ApoptosisJournal of Experimental Medicine, 1997
- Reference range data base for serum chemistry and hematology values in laboratory animalsJournal of Toxicology and Environmental Health, 1986